A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

Oliver G. Ottmann, Brian Druker, Charles L. Sawyers, John M. Goldman, Jose Reiffers, Richard T. Silver, Sante Tura, Thomas Fischer, Michael W. Deininger, Charles A. Schiffer, Michele Baccarani, Alois Gratwohl, Andreas Hochhaus, Dieter Hoelzer, Sofia Fernandes-Reese, Insa Gathmann, Renaud Capdeville, Stephen G. O'Brien

Research output: Contribution to journalArticle

462 Citations (Scopus)

Abstract

The translocation (9;22) gives rise to the p190 Bcr-Abl and p210 Bcr-Abl tyrosine kinase proteins, considered sufficient for leukemic transformation. Philadelphia-positive (Ph +) acute leukemia patients failing to respond to initial induction therapy have a poor prognosis with few effective treatment options. Imatinib is an orally administered, potent inhibitor of the Bcr-Abl tyrosine kinase. We conducted a clinical trial in 56 patients with relapsed or refractory Ph + acute lymphoblastic leukemia (ALL; 48 patients) or chronic myelogenous leukemia in lymphoid blast crisis (LyBC; 8 patients). Imatinib was given once daily at 400 mg or 600 mg. Imatinib induced complete hematologic responses (CHRs) and complete marrow responses (marrow-CRs) in 29% of ALL patients (CHR, 19%; marrow-CR, 10%), which were sustained for at least 4 weeks in 6% of patients. Median estimated time to progression and overall survival for ALL patients were 2.2 and 4.9 months, respectively. CHRs were reported for 3 (38%) of the patients with LyBC (one sustained CHR). Grade 3 or 4 treatment-related nonhematologic toxicity was reported for 9% of patients; none of the patients discontinued therapy because of nonhematologic adverse reactions. Grade 4 neutropenia and thrombocytopenia occurred in 54% and 27% of patients, respectively. Imatinib therapy resulted in a clinically relevant hematologic response rate in relapsed or refractory Ph + acute lymphoid leukemia patients, but development of resistance and subsequent disease progression were rapid. Further studies are warranted to test the effects of imatinib in combination with other agents and to define the mechanisms of resistance to imatinib.

Original languageEnglish (US)
Pages (from-to)1965-1971
Number of pages7
JournalBlood
Volume100
Issue number6
DOIs
StatePublished - Sep 15 2002

Fingerprint

Philadelphia Chromosome
Chromosomes
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Refractory materials
bcr-abl Fusion Proteins
Bone Marrow
Toxicity
Imatinib Mesylate
Blast Crisis
Therapeutics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neutropenia
Disease Progression
Leukemia
Proteins

ASJC Scopus subject areas

  • Hematology

Cite this

Ottmann, O. G., Druker, B., Sawyers, C. L., Goldman, J. M., Reiffers, J., Silver, R. T., ... O'Brien, S. G. (2002). A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood, 100(6), 1965-1971. https://doi.org/10.1182/blood-2001-12-0181

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. / Ottmann, Oliver G.; Druker, Brian; Sawyers, Charles L.; Goldman, John M.; Reiffers, Jose; Silver, Richard T.; Tura, Sante; Fischer, Thomas; Deininger, Michael W.; Schiffer, Charles A.; Baccarani, Michele; Gratwohl, Alois; Hochhaus, Andreas; Hoelzer, Dieter; Fernandes-Reese, Sofia; Gathmann, Insa; Capdeville, Renaud; O'Brien, Stephen G.

In: Blood, Vol. 100, No. 6, 15.09.2002, p. 1965-1971.

Research output: Contribution to journalArticle

Ottmann, OG, Druker, B, Sawyers, CL, Goldman, JM, Reiffers, J, Silver, RT, Tura, S, Fischer, T, Deininger, MW, Schiffer, CA, Baccarani, M, Gratwohl, A, Hochhaus, A, Hoelzer, D, Fernandes-Reese, S, Gathmann, I, Capdeville, R & O'Brien, SG 2002, 'A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias', Blood, vol. 100, no. 6, pp. 1965-1971. https://doi.org/10.1182/blood-2001-12-0181
Ottmann, Oliver G. ; Druker, Brian ; Sawyers, Charles L. ; Goldman, John M. ; Reiffers, Jose ; Silver, Richard T. ; Tura, Sante ; Fischer, Thomas ; Deininger, Michael W. ; Schiffer, Charles A. ; Baccarani, Michele ; Gratwohl, Alois ; Hochhaus, Andreas ; Hoelzer, Dieter ; Fernandes-Reese, Sofia ; Gathmann, Insa ; Capdeville, Renaud ; O'Brien, Stephen G. / A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. In: Blood. 2002 ; Vol. 100, No. 6. pp. 1965-1971.
@article{16e4b94aaeac4acc8fb0165c5fdf6b9e,
title = "A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias",
abstract = "The translocation (9;22) gives rise to the p190 Bcr-Abl and p210 Bcr-Abl tyrosine kinase proteins, considered sufficient for leukemic transformation. Philadelphia-positive (Ph +) acute leukemia patients failing to respond to initial induction therapy have a poor prognosis with few effective treatment options. Imatinib is an orally administered, potent inhibitor of the Bcr-Abl tyrosine kinase. We conducted a clinical trial in 56 patients with relapsed or refractory Ph + acute lymphoblastic leukemia (ALL; 48 patients) or chronic myelogenous leukemia in lymphoid blast crisis (LyBC; 8 patients). Imatinib was given once daily at 400 mg or 600 mg. Imatinib induced complete hematologic responses (CHRs) and complete marrow responses (marrow-CRs) in 29{\%} of ALL patients (CHR, 19{\%}; marrow-CR, 10{\%}), which were sustained for at least 4 weeks in 6{\%} of patients. Median estimated time to progression and overall survival for ALL patients were 2.2 and 4.9 months, respectively. CHRs were reported for 3 (38{\%}) of the patients with LyBC (one sustained CHR). Grade 3 or 4 treatment-related nonhematologic toxicity was reported for 9{\%} of patients; none of the patients discontinued therapy because of nonhematologic adverse reactions. Grade 4 neutropenia and thrombocytopenia occurred in 54{\%} and 27{\%} of patients, respectively. Imatinib therapy resulted in a clinically relevant hematologic response rate in relapsed or refractory Ph + acute lymphoid leukemia patients, but development of resistance and subsequent disease progression were rapid. Further studies are warranted to test the effects of imatinib in combination with other agents and to define the mechanisms of resistance to imatinib.",
author = "Ottmann, {Oliver G.} and Brian Druker and Sawyers, {Charles L.} and Goldman, {John M.} and Jose Reiffers and Silver, {Richard T.} and Sante Tura and Thomas Fischer and Deininger, {Michael W.} and Schiffer, {Charles A.} and Michele Baccarani and Alois Gratwohl and Andreas Hochhaus and Dieter Hoelzer and Sofia Fernandes-Reese and Insa Gathmann and Renaud Capdeville and O'Brien, {Stephen G.}",
year = "2002",
month = "9",
day = "15",
doi = "10.1182/blood-2001-12-0181",
language = "English (US)",
volume = "100",
pages = "1965--1971",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

AU - Ottmann, Oliver G.

AU - Druker, Brian

AU - Sawyers, Charles L.

AU - Goldman, John M.

AU - Reiffers, Jose

AU - Silver, Richard T.

AU - Tura, Sante

AU - Fischer, Thomas

AU - Deininger, Michael W.

AU - Schiffer, Charles A.

AU - Baccarani, Michele

AU - Gratwohl, Alois

AU - Hochhaus, Andreas

AU - Hoelzer, Dieter

AU - Fernandes-Reese, Sofia

AU - Gathmann, Insa

AU - Capdeville, Renaud

AU - O'Brien, Stephen G.

PY - 2002/9/15

Y1 - 2002/9/15

N2 - The translocation (9;22) gives rise to the p190 Bcr-Abl and p210 Bcr-Abl tyrosine kinase proteins, considered sufficient for leukemic transformation. Philadelphia-positive (Ph +) acute leukemia patients failing to respond to initial induction therapy have a poor prognosis with few effective treatment options. Imatinib is an orally administered, potent inhibitor of the Bcr-Abl tyrosine kinase. We conducted a clinical trial in 56 patients with relapsed or refractory Ph + acute lymphoblastic leukemia (ALL; 48 patients) or chronic myelogenous leukemia in lymphoid blast crisis (LyBC; 8 patients). Imatinib was given once daily at 400 mg or 600 mg. Imatinib induced complete hematologic responses (CHRs) and complete marrow responses (marrow-CRs) in 29% of ALL patients (CHR, 19%; marrow-CR, 10%), which were sustained for at least 4 weeks in 6% of patients. Median estimated time to progression and overall survival for ALL patients were 2.2 and 4.9 months, respectively. CHRs were reported for 3 (38%) of the patients with LyBC (one sustained CHR). Grade 3 or 4 treatment-related nonhematologic toxicity was reported for 9% of patients; none of the patients discontinued therapy because of nonhematologic adverse reactions. Grade 4 neutropenia and thrombocytopenia occurred in 54% and 27% of patients, respectively. Imatinib therapy resulted in a clinically relevant hematologic response rate in relapsed or refractory Ph + acute lymphoid leukemia patients, but development of resistance and subsequent disease progression were rapid. Further studies are warranted to test the effects of imatinib in combination with other agents and to define the mechanisms of resistance to imatinib.

AB - The translocation (9;22) gives rise to the p190 Bcr-Abl and p210 Bcr-Abl tyrosine kinase proteins, considered sufficient for leukemic transformation. Philadelphia-positive (Ph +) acute leukemia patients failing to respond to initial induction therapy have a poor prognosis with few effective treatment options. Imatinib is an orally administered, potent inhibitor of the Bcr-Abl tyrosine kinase. We conducted a clinical trial in 56 patients with relapsed or refractory Ph + acute lymphoblastic leukemia (ALL; 48 patients) or chronic myelogenous leukemia in lymphoid blast crisis (LyBC; 8 patients). Imatinib was given once daily at 400 mg or 600 mg. Imatinib induced complete hematologic responses (CHRs) and complete marrow responses (marrow-CRs) in 29% of ALL patients (CHR, 19%; marrow-CR, 10%), which were sustained for at least 4 weeks in 6% of patients. Median estimated time to progression and overall survival for ALL patients were 2.2 and 4.9 months, respectively. CHRs were reported for 3 (38%) of the patients with LyBC (one sustained CHR). Grade 3 or 4 treatment-related nonhematologic toxicity was reported for 9% of patients; none of the patients discontinued therapy because of nonhematologic adverse reactions. Grade 4 neutropenia and thrombocytopenia occurred in 54% and 27% of patients, respectively. Imatinib therapy resulted in a clinically relevant hematologic response rate in relapsed or refractory Ph + acute lymphoid leukemia patients, but development of resistance and subsequent disease progression were rapid. Further studies are warranted to test the effects of imatinib in combination with other agents and to define the mechanisms of resistance to imatinib.

UR - http://www.scopus.com/inward/record.url?scp=0037105560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037105560&partnerID=8YFLogxK

U2 - 10.1182/blood-2001-12-0181

DO - 10.1182/blood-2001-12-0181

M3 - Article

VL - 100

SP - 1965

EP - 1971

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -